Section Review—Oncologic, Endocrine & Metabolic: Potential Use of Vanadium Compounds in the Treatment of Diabetes Mellitus

References

• SUSRUTA SAMHITA (500 N. Chr.): BD 1–3 Calcutta 1907–1916 (as cited in reference 2, below).
   Google Scholar
• SCHADEWALDT H: The history of diabetes mellitus. Ire Diabetes: its medical and cultural history. Van Engelhardt D (Ed.). Springer Verlag, Berlin (1987):43–100.
   Google Scholar
• KING H, REWERS M: Global estimates for prevalence of diabetes mellitus and impaired glucose tolerance in adults. Diabetes Care (1993) 16:157–177.
   PubMed Web of Science ®Google Scholar
• BANTING FG, BEST CH: Internal secretion of the pan-creas. J. Lab. Clin. Med. (1922) 7:251–266.
   Google Scholar
• GROOP LC: Sulfonylureas in NTDDM. Diabetes Care (1992)15:737–754.
   PubMed Web of Science ®Google Scholar
• BAILEY CJ: Biguanides and NIDDM. Diabetes Care (1992)15:755–772.
   PubMed Web of Science ®Google Scholar
• TOLMAN EL. BARRIS E, BURNS M, PANSINI A, PARTRIDGE •R: Effects of vanadium on glucose metabolism in vitro.Life Set. (1979) 25:1159-1164. First report demonstrating insulinomimetic effect of vanadium com-pounds.
   Google Scholar
• SHECHTER Y, KARLISH SJD: Insulin-like stimulation of glucose oxidation in rat adipocytes by vanadyl (IV) ions. Nature (1980) 284:556–558.
   PubMed Web of Science ®Google Scholar
• DUBYAK GR, KLEINZELLER A: The insulin-mimetic ef- fects of vanadate as (Na,ATPase inhibitor. J. Biol.Chem. (1980) 255:5306–5312.
   PubMed Web of Science ®Google Scholar
• SINGH J, NORDL1S RC, JORGENSON RA: Vanadate: apotent inhibitor of multifunctional glucose-6-phos-phatase. Biochem. Biophys. Acta (1981) 678:477–482.
   PubMed Web of Science ®Google Scholar
• DEGANI H, GOCH1N M, KARLISH SJO, SHECH IER Y: Elec-tron paramagnetic resonance studies and insulin-like effects of vanadium in rat adipocytes. Biochemistry (1981) 20:5795–5799.
   PubMed Web of Science ®Google Scholar
• CARPENTIER G: Vanadate, epidermal growth factor andthe stimulation of DNA synthesis. Biochem. Biophys. Res. Commun. (1982) 102:1115–1121.
   Web of Science ®Google Scholar
• SMITH JB: Vanadium ions stimulate DNA synthesis in Swiss mouse 3T3 and 3T6 cells. Pn9c. Natl. Acad. Sci. USA (1983) 80:6162–6166.
   PubMed Web of Science ®Google Scholar
• TAMURA S, BROWN TA, WHIPPLE J11, YAMAGUCHI YF, DUBLER RE, CHEN K, LARNER J: A novel mechanism of the insulin-like effects of vanadate on glycogen syn-thase in rat adipocytes. J. Biol. Chem. (1984) 259:6650–6658.
   PubMed Web of Science ®Google Scholar
• CLARK AS, FAGAN JM, MITCH WE: Selectivity of theInsulin-like actions of vanadate on glucose and protein metabolism in skeletal muscle. Biochem. J. (1985) 232 :273–276.
   PubMed Web of Science ®Google Scholar
• DELFERT DM, McDONALD JM: Vanadyl and vanadate Inhibit Ca.' transport systems of the adipocyte plasma membrane and endoplasmic reticulum. Arch. Biochem. Biophys. (1985) 241:665–672.
   PubMed Web of Science ®Google Scholar
• KLARLUND JR: Transformation of cells by an inhibitor of phosphatases acting on phosphotyrosine in pro-teins. Cell (1985) 41:707–717.
   PubMed Web of Science ®Google Scholar
• GREEN A: The insulin like effect of sodium vanadate on adipocyte glucose transport is mediated at a post-insu-lin-receptor level_ Biochem. J. (1986) 238:663–669.
   Google Scholar
• BOSCH F, ARINO J, GOMEZ-FOIX AM, GUINOVART JJ: Glycogenolytic noninsulin-like effects of vanadate on rat hepatocyte glycogen synthase and phosphorylase. J. Biol. Chem. (1987) 262:218–222.
   PubMed Web of Science ®Google Scholar
• GOMEZ-FOIX AM, RODRIGUEZ-GIL JE, FILLAT C, GUINO-VART JJ, BOSCH F: Vanadate raises fructose 2,6-bisphos-phate concentrations and activates glycolysis in rat hepatocytes. Biochem. J. (1988) 255:507–512.
   PubMed Web of Science ®Google Scholar
• JACKSON TK, SALHANICK Al, SPARKS JD, SPARKS CE, BOLOGNINO M, AMATRUDA JM: Insulin mimetic effects of vanadate in primary cultures of rat hepatocytes. Diabetes (1988) 37:1234–1240.
   PubMed Web of Science ®Google Scholar
• DUCKWORTH WC, SOLOMON SS, LIEPNICKS J, HAMEL FG,HAND S, PEAVY DE: Insulin-like effects of vanadate in Isolated rat adipocytes. Endocrinology (1988) 122:2285–2289.
   PubMed Web of Science ®Google Scholar
• FANTUS IG, KADOTA SI, DERAGON G, FOSTER B, POSNER BI: Pervanadate (peroxide(s) of vanadate) mimics insu-lin action in rat adipocytes via activation of the insulin receptor tyrosine kinase. Biochemistry (1989) 28:8864-8871. First report showing insulinomimetic effects of pervanadate.
   Google Scholar
• RODRIGUEZ-GIL JE, GOMEZ-FOIX AM, ARINO J, GUN- IOVART JJ, BOSCH F: Control of glycogen synthase and phosphorylase in hepatocytes from diabetic rats. Dia-betes (1989) 38.793–798.
   PubMed Web of Science ®Google Scholar
• MIRALPEIX M, GIL J, ROSA JC, CARRERAS J, BARTRONS R: Vanadate counteracts glucagon effects in isolated rat hepatocytes. Life Sci. (1989) 44:1491–1497.
   PubMed Web of Science ®Google Scholar
• RIDER MH, BARTRONS R, HUE L: Vanadate inhibits liver fructose-2,6-bisphosphatase. Dir. J. Biochem. (1990) 209:53–56.
   Google Scholar
• MOUNTJOY KG, FLIER JS: Vanadate regulates glucose transporter (Glut-1) expression in NIH 3T3 mouse fi-broblasts. Endocrinology (1990) 26:2778–2787.
   Google Scholar
• MIRALPEIX M, DECAUX JF, KAHN A, BARTRONS R: Vanadate induction of L-type pyruvate kinase mRNA in adult rat hepatocytes in primary culture. Diabetes (1991) 40:462–464.
   PubMed Web of Science ®Google Scholar
• HEYLIGER CE, TAHILIANI AG, McNEILL JH: Effect of •vanadate on elevated blood glucose and depressedcardiac performance of diabetic rats. Science (1985) 277:1474-1477. First report showing the glucose lowering effect of sodium or-thovanadate in STZ-diabetic animal model of (IDDM) diabetes mellitus.
   Google Scholar
• MEYEROVITCH J, FARFEL Z, SACK J, SITECHTER Y: Oraladministration of vanadate normalizes blood glucose levels in streptozotocin-treated rats. J. Biol. Chem. (1987) 262:6658–6662.
   PubMed Web of Science ®Google Scholar
• BRICHARD SM, POTTIER AM, HENQUIN JC: Long term improvement of glucose homeostasis by vanadate in obese hyperinsulinemicfa /fa rats. Endocrinology (1989) 125:2510-2516. First report showing glucose lowering effect of vanadate in type II model of diabetes.
   Google Scholar
• PUGAZHENTHI S, ANGEL JF, KHANDELWAL RLZ: Long-term effects of vanadate treatment on glycogen meta-bolizing and lipogenic enzymes of liver in genetically diabetic (db /db) mice. Metabolism (1991) 40:941–946.
   PubMed Web of Science ®Google Scholar
• MEYEROVITCH J, ROTHENBERG P. SHECHTER Y, BON-NER-WEIR S, KAHN CR: Vanadate normalizes hypergly-cemia in two mouse models of non-insulin-dependent diabetes mellitus. J. Clin. Invest. (1991) 87:1286–1294.
   PubMed Web of Science ®Google Scholar
• SHECIITER Y: Insulin-mimetic effects of vanadate: Pos-sible implications for future treatment of diabetes. Diabetes (1990) 39:1-5. An excellent review documenting various insulinomimetic effects of vanadium compounds.
   Google Scholar
• NECHAY BR: Mechanisms of action of vanadium. Ann.
   Google Scholar
• ••Rev. Pharmacol. Taxicol. (1984) 24:501-524. Excellent review on vanadium compounds and their biological action.
   Google Scholar
• RAMASARMA T, CRANE FL: Does vanadium play a role in •cellular regulation? Curr. Topics Cell. Regul. (1981) 20:247-301. First detailed review on vanadium compounds.
   Google Scholar
• CHASTEEN ND: The biochemistry of vanadium. In: Struc-ture and bonding. Springer Verlag, Berlin, Heidelberg (1983) 53:105-138. An excellent review on chemistry and biochemistry of vanadium compounds.
   Google Scholar
• ROBINSON KA: Concerning the form of biochemically active vanadium. Proc. Royal Soc. London Series B (1981) 212:65–84.
   PubMed Web of Science ®Google Scholar
• FRENCH RJ, JONES PJH: Role of vanadium in nutrition:metabolism, essentiality and dietary considerations. Life Sci. (1992) 52:339–346.
   Web of Science ®Google Scholar
• BYRNE AR, KOSTA L: Vanadium in foods and in humanbody fluids and tissues. Sci. Total Environ. (1978) 10:17–30.
   PubMed Web of Science ®Google Scholar
• LYONNET B, MARTZ, MARTIN E: L'emploi thérapeutique •des derivés du vanadium. La Presse Médicale (1989) (22avril) 32:191–192.
   Google Scholar
• STROUT ITV, VICARIO PP, SAPERSTE1N R, SLATER EE: Theinsulin-mimetic effect of vanadate is not correlated with Insulin receptor tyrosine kinase activity nor phospho-rylation in mouse diaphragm in vivo. Endocrinology (1989) 124: 1918-1924.
   Google Scholar
• SI IISI1EVA A, SI1ECHTER Y: Quercetin selectively inhibitsinsulin receptor function in vitro and the bioresponse of insulin and insulinomitnetic agents in rat adipocytes. Biochemistry (1992) 31:8059–8063.
   PubMedGoogle Scholar
• JUNOD A, LAMBERT AE, STAUFFACIIER W, RENOLD AE:Diabetogenic action of streptozotocin: relationship of dose to metabolic response. J. Clin. Invest. (1969) 48: 2129–2139.
   PubMed Web of Science ®Google Scholar
• KARASIK A, HATTORI M: Use of animal models in studyof diabetes. In: Joselin's Diabetes Mellitus (13th Edition). Kahn CR, Weir GR (Eds.). Lea & Febiger Publishers, Malvem, Pennsylvania (1994)317–350.
   Google Scholar
• GIL J, MIRALPR1X M, CARRERAS J, BARTRONS R: Insulin-like effects of vanadate on glucolcinase activity and fructose 2,6-biphosphate levels in the liver of diabetic rats. J. Biol. Chem. (1988) 263:1868–1871.
   PubMed Web of Science ®Google Scholar
• BRICHARD SM, OKITOLONDA W, HENQUIN JC: Long termImprovement of glucose homeostasis by vanadate treat-ment in diabetic rats. Endocrinology(1988) 123:2048–2053.
   PubMed Web of Science ®Google Scholar
• BLONDEL 0, BAILBE D, PORTHA B: In vivo insulinresistance in streptozotocin-diabetic rats - evidence for reversal following oral vanadate treatment Diabetologia (1989) 32:185–190.
   Google Scholar
• BENTDAYAN M, GINGRAS D: Effects of vanadate admini-stration on blood glucose and insulin levels as well as on the exocrine pancreatic function in streptozotocin-diabetic rats. Diabetologia (1989) 32:561–567.
   PubMed Web of Science ®Google Scholar
• RAMANADHAM S, MONGOLD JJ, BROWNSEY RW, CROSGH, McNEILL JH: Oral vanadyl sulphate in treatment of diabetes mellitus in rats. Am. J. Physiol. (1989) 257:H904–H911.
   PubMed Web of Science ®Google Scholar
• PUGAZHENTHI S, KHANDELWAL RL: Insulin-like effectsof vanadate on hepatic glycogen metabolism in nondi-abetic and streptozotocin-induced diabetic rats. Diabetes (1990) 39:821–827.
   PubMedGoogle Scholar
• ROSSETTI L, LAUGHLIN MR: Correction of chronic hy-perglycemia with vanadate, but not with phlorizine, normalizes in vivo glycogen repletion and in vitro glycogen synthase activity in diabetic skeletal muscle. J. Clin. Invest. (1989) 84:892–899.
   PubMedGoogle Scholar
• BOLLEN M, MIRALPELX M, VENTURA F, TOTH B, BAR-TRONS R, STALMANS W: Oral administration of vanadate to streptozotocin-diabetic rats restores the glucose-in-duced activation of liver glycogen synthase. Biochem. J. (1990) 267:269–271.
   PubMed Web of Science ®Google Scholar
• STROUT HV, VICARIO PP, BISWAS C, SUPERSTE1N R,BRADY EJ, FILCH PF, BERGER J: Vanadate treatment of streptozotocin diabetic rats restores expression of the insulin responsive glucose transporter in skeletal mus-cle. Endocrinology (1990) 126:2728–2732.
   PubMed Web of Science ®Google Scholar
• SEKAR N, KANTF1ASAMY A, WILLIAM 5, SUBRAMAN1AN 5,GOV1NDASAMY S: Insulin actions of vanadate in diabetic rats. Pharmacological Research (1989) 22:207–217.
   Web of Science ®Google Scholar
• SAKURAI H, TSUCHIYA K, NUKATSUKA M, SOFTIE M, KAWADA J: Insulin-like effects of vanadyl ion on strep-tozotocin-induced diabetic rats. J. Endocrinol. (1990) 126:451–459.
   PubMed Web of Science ®Google Scholar
• VENKATESAN N, AVIDAN A, DAVIDSON MB: Antidiabetic action of vanadyl in rats independent of in vivo insu-lin-receptor kinase activity. Diabetes (1991) 40:492–498.
   PubMed Web of Science ®Google Scholar
• DOMINGO JL, GOMEZ M, LLOBET JM, CORBELLA J, KEEN CL: Oral vanadium administration to streptozotocin-diabetic rats has marked negative side-effects which are independent of the form of vanadium used. Toxicology (1991) 66:279–287.
   PubMed Web of Science ®Google Scholar
• DOMINGO JL, GOMEZ M, LLOBET JM, CORBELLA J, KEEN CL: Improvement of glucose homeostasis by oral vanadyl or vanadate treatment in diabetic rats is accom-panied by negative side effects. Pharmacology and Toxi-cology (1991) 68:249–253.
   PubMed Web of Science ®Google Scholar
• SAXENA AK, SRIVASTAVA P, BACQUER NZ: Effects of vanadate on glycolytk enzymes and malic enzyme in Insulin-dependent and-independent tissues of diabetic rats. Eur. J. Pharmacol. (1992) 216:123–126.
   PubMed Web of Science ®Google Scholar
• OSTER MIT, LLOBET JM, DOMINGO JL, GERMAN JB, KEEN CL: Vanadium treatment of diabetic Sprague-Dawley rats results in tissue vanadium accumulation and pro-oxidant effects. Toxicology (1993) 83:115–130.
   PubMed Web of Science ®Google Scholar
• MADSEN KL, PORTER VM, FEDORAK RN: Oral vanadate reduces NaC)-dependent glucose transport in rat small Intestine. Diabetes (1993) 42:1126–1132.
   PubMed Web of Science ®Google Scholar
• VALERA A, RODRIGUEZ-GIL JE, BOSCH F: Vanadate treat-ment restores the expression of genes for key enzymes In the glucose and ketone bodies metabolism in the liver of diabetic rats. J. Clin. Invest. (1993) 92:4–11.
   PubMed Web of Science ®Google Scholar
• MALABU LTH, DRYDEN S, MCCARTHY FID, KILPATRICK A, WILLIAMS G: Effects of chronic vanadate administration in the STZ-induced diabetic rat: the antihyperglycemic action of vanadate is attributable entirely to its suppres-sion of feeding. Diabetes (1994) 43:9–15.
   PubMed Web of Science ®Google Scholar
• PEDERSON RA, RAMANADHAM 5, BUCHAN A, McNEILL JI I: Long-term effects of vanadyl treatment on streptozoto-cin-induced diabetes in rats. Diabetes (1989) 38:1390–1395.
   PubMed Web of Science ®Google Scholar
• BECKER DJ, ONGEMBA L-N, HENQUIN JC: Comparison ofthe effects of various vanadium salts on glucose homeo-stasis in streptozotocin-diabetic rats. Eur. J. Pharmacol. (1994) 260:169–175.
   PubMed Web of Science ®Google Scholar
• McNEILL JH, YUEN VG, HOVEYDA HR, ORV1G C: Ills (maltolato) oxovanadium (IV) is a potent insulin mimic. J Med. Chem. (1992) 35:1489-1491. First report showing the glucose lowering effect of organic vanadium compounds.
   Google Scholar
• THEN VG, ORV1G G, MCNEILL JH: Glucose lowering effectof a new organic vanadium complex, bis (maltolato) oxovanadium (IV). Can. J. Physiol. Pharmacol. (1993) 71: 263–269.
   PubMed Web of Science ®Google Scholar
• THEN VG, ORVIG C, THOMPSON KII, McNEILL JH: Im-provement in cardiac dysfunction in streptozotocin-in-duced diabetic rats following chronic oral administration of bis (maltolato) oxo-vanadium (IV). Can. J. Physiol. Pharmacol. (1993) 71:270–276.
   PubMed Web of Science ®Google Scholar
• LEIGHTON B, COOPER GJS, DACOSTA C, FOOT EA: Per-oxovanadates have full insulin-like effects on glycogen synthesis in normal and insulin-resistant skeletal mus-cle. Biochem.J. (1991) 276:289–292.
   PubMed Web of Science ®Google Scholar
• SHISHEVA A, IKONOMOV 0, SHECHTER Y: The protein tyrosine phosphatase inhibitor, pervanadate, is a pow-erful antidiabetic agent in streptozotocin-treated dia-betic rats. Endocrinology (1994) 134:507-510. First report showing glucose lowering effects of pervanadate in STZ-diabetic rats.
   Google Scholar
• POSNER BI, FAURE R, BURGESS JW, BEVAN AP, LACIIANCE D, ZHANG-SUN G, FANTUS IG, NG JB, HALL DA, LUM BS, SHAVER A: Peroxovanadium compounds: A new class of potent phosphatase inhibitors which are insulin mixnetics. J. Biol. Chem. (1994) 269:4596-4604. First report showing glucose lowering effect of peroxovanadium compounds.
   Google Scholar
• YALE JF, LACHANCE D, VIGEANT C, SHAVER A, POSNER BI: In vivo effects of peroxovanadiurn compounds in diabetic BB rats. Can. J. Physiol. Pharmacol. (1994) 72\(Suppl. 3):11.
   Google Scholar
• BRICHARD SM, BAILEY CJ, HENQUIN J-C: Marked im-provement of glucose homeostasis in diabetic ob/ob mice given oral vanadate. Diabetes (1990) 39:13266–13332.
   Google Scholar
• PUGAZHENTHI S, ANGEL JF, KHANDELWAL RL: Effects of vanadate administration on the high sucrose diet-in-duced aberrations in normal rats. Mot Cell. Biochem. (1993) 122:69–75.
   PubMed Web of Science ®Google Scholar
• GOLDFINE AB, FOLLI F, PATTI ME, SIMONSON DC, KAHN CR: Clinical trials of vanadium compounds in human diabetes mellitus. Can. J. Physiol. Pbarmacol. (1994) 72\(Suppl. 3):11.
   Google Scholar
• ROSSETTI L, COHEN N, HALBERSTAM M, SHLIMOVICH P, HUM, SHAMOON, II: In vivo metabolic effects of vana-dium on skeletal muscle and hepatic glucose metabo-lism. Can. J. Physiol. Pharmacol. (1994) 72\(Suppl. 3):P11.
   Google Scholar
• BRICHARD SM, DESBUQUOIS B, GIRARD J: Vanadate treatment of diabetic rats reverses the impaired expres-sion of genes involved in hepatic glucose metabolism: effects on glycolytic and gluconeogenic enzymes and on glucose transporter GLUT2. Mot Cell. Endocrinot (1993) 91:91–97.
   PubMed Web of Science ®Google Scholar
• MIRALPEIX M, CARBALLO E, BARTRONS R, CREPIN K, HUE L, ROUSSEAU GG: Oral administration of vanadate to diabetic rats restores liver 6-phosphofructo-2-kinase content and mRNA. Diabetologia (1992) 35:243–248.
   PubMed Web of Science ®Google Scholar
• PUGAZHENTHI S, KHANDELWAL RL, ANGEL JF: Insulin like effects of vanadate on mane enzyme and glucose-6-phosphate dehydrogenase activities in stre ptozoto-chi-induced diabetic rat liver. Biochim. Biophys. Acta (1991) 1083:310–312.
   PubMed Web of Science ®Google Scholar
• BRICHARD SM, ONGEMBA LN, GIRARD J, HENQUIN JC:Tissue specific correction of lipogenk enzyme gene expression in diabetic rats given vanadate. Diabetologia (1994) 37:1065–1072.
   PubMed Web of Science ®Google Scholar
• BERNIER M, LAIRD DM, LANE MD: Effect of vanadate onthe cellular accumulation of pp15, an apparent product of insulin receptor tyrosine kinase action. J. Biol. Chem. (1988) 263:13626–13634.
   PubMed Web of Science ®Google Scholar
• GHERZI R, CARATTI C, ANDRAGHETTI G, BERTOLINI S,MONTEMURRD A, SESTI G, CORDERA R: Direct modula-tion of insulin receptor protein tyrosine kinase by vanadate and anti-insulin receptor monoclonal anti- bodies. Biochem. Biophys. Res. Commun. (1988) 152:1474–1480.
   PubMedGoogle Scholar
• PUGAZITENTFII S, KIIANDELWAL RL: Does the insulin-mi-metic action of vanadate involve insulin receptor ki-nase? Mol. Cell. Biochem. (1993) 217–218 211–218
   Google Scholar
• MOONEY RA, BORDWELL KL, LUI IOWSKY S, CASNELLI JE:The insulin-like effect of vanadate on lipolysis in rat adipocytes is not accompanied by an insulin-like effect on tyrosine phosphorylation. Endocrinology (1989) 124:422–429.
   PubMed Web of Science ®Google Scholar
• BLONDEL 0, SIMON J, CHEVALIER B, PORTHA B: Im-paired insulin action but normal insulin receptor activ-ity in diabetic rat liver: effect of vanadate. Am.J. Physiol. (1990) 2581.459–E467.
   Google Scholar
• D'ONOFRIO F, LE MQ, CHIASSON J-L, SRIVASTAVA AK: Vanadate dependent activation of mitogen activated protein (MAP) kinase in Chinese hamster ovary cells overexpressing a wild type human insulin receptor (CHO-HIRc). The Pharmacologist (1993) 35:109.
   Google Scholar
• D'ONOFRIO F, LE MQ, CHIASSON J-L, SRIVASTAVA AK: Activation of mitogen activated protein (MAP) kinases by vanadate is independent of insulin receptor auto-phosphorylation. FEBS Lett. (1994) 340:269–275.
   PubMedGoogle Scholar
• OLEFSKY JM: The insulin receptor: a multifunctional protein. Diabetes (1990) 3A:1009–1116.
   Google Scholar
• MYERS MG, WHITE MF: The new elements of insulin signaling: insulin receptor substrate-1 and proteins with SH2 domains. Diabetes (1993) 42:643–650.
   PubMed Web of Science ®Google Scholar
• WHITE MF, KAHN CR: The insulin signaling system. J.Biol. Chem. (1994) 269:1–4.
   PubMed Web of Science ®Google Scholar
• SWARUP G, COHEN S, GARBERS DL: Inhibition of mem-brane phosphotyrosyl protein phosphatase activity by vanadate. Biochem. Biophys. Res. Commun. (1982) 107:1104–1109.
   PubMed Web of Science ®Google Scholar
• FANTUS IG, AHMAD F, DERAGON G: Vanadate augments Insulin binding and prolongs insulin action in rat adipocytes. Endocrinology (1990) 127:2716–2725.
   PubMed Web of Science ®Google Scholar
• FANTUS IG, AFIMAD F, DERAGON G: Vanadate augments insulin stimulated tyrosine kinase activity and prolongs insulin action in rat adipocytes: evidence for transduc-tion of amplitude of signaling into duration of re-sponse. Diabetes (1994) 43:375–383.
   PubMed Web of Science ®Google Scholar
• SHISHEVA A, SHECHTER Y: Role of cytosolic tyrosine kinase in mediating insulin-like actions of vanadate in rat adipocytes. J. Biol. Chem. (1993) 268:6463–6469.
   PubMed Web of Science ®Google Scholar
• CHEATHAM B, VLAHOS CJ, CHEATHAM L, WANG L, BLENIS J, KAHN CR: Phosphatidyl inosito13-kinase activation is required for insulin stimulation of pp70s6k, DNA syn-thesis, and glucose transporter translocation. Mol. Cell. Biol. (1994) 14:4902–4911.
   PubMed Web of Science ®Google Scholar
• CROSS DAE, ALESSI DR, VADENHEEDE JR, McDOWELL ILE,HUNDAL HS, COHEN P: The inhibition of glycogen synthase kinase-3 by insulin or insulin-like growth factor 1 in the rat skeletal muscle cell line L6 is blocked by wortmamfin, but not by rapamycin: evidence that wortmanunin blocks activation of the mitogen activated protein kinase pathway in 1,6 cells between ras and raf. Biochem. J. (1994) 303:21–26.
   PubMedGoogle Scholar
• WELSH GI, FOULSTONE EJ, YOUNG SW, TAVARE JM, PROUD CG: Wortmannin inhibits the effect of insulin and serum on the activities of glycogen synthase kinase- 3 and mitogen activated protein kinase. Biochem. J. (1994) 303:15–20.
   PubMed Web of Science ®Google Scholar
• SHEPIIERD PR, NAVE BT, SIDDLE K: Insulin stimulationof glycogen synthesis and glycogen synthase activity is blocked by worttnannin and rapamycin in 3T3-L1 adipocytes: evidence for the involvement of phospho-inositide 3-kinase and p70 ribosomal proteins 6 kinase. Biochem. J. (1995) 305:25–28.
   PubMed Web of Science ®Google Scholar
• HADAR1 YR, TZAHAR E, NADIV 0, ROTHENBERG P, ROBERTS JR, LE ROITI I D, YARDEN Y, ZICK Y: Insulin and insulinomhnetic agents induce activation of phospha-tidylinositol 3-kinase HIS-1 in intact rat livers. J. Biol. Chem. (1992) 267:17483–17486.
   PubMedGoogle Scholar
• SRIVASTAVA AK: Activation of serine/threonine kinase by vanadium compounds. Can. J. Physiol, Pharmacol. (1994) 72\(Suppl. 3):9.
   Google Scholar
• D'ONOFRIO F, CHIASSON J-L, SRIVASTAVA AK: Hydrogen peroxide and pervanadate-induced phosphorylation and activation of mitogen activated protein (MAP) ki-nases. Can. J. Physiol. Pharrnacol. (1994) 72\(Suppl. 3): 19.
   Google Scholar
• PANDEY SK, CHIASSON JL, SRIVASTAVA AK: Vanadium compounds stimulate mitogen activated protein (MAP) kinase and ribosomal S-6-kinases. Mol. Cell. Biocbem. (1995). In press.
   Google Scholar
• BERGER J, HAYES N, SZALKOWSKI DM, ZHANG 13: P13-ki-nase activation is required for insulin stimulation of glucose transport into L6 myotube. Biochem. Biophys. Res. Commun. (1994) 205:570–576.
   PubMed Web of Science ®Google Scholar
• DOMINGO JL, GOMEZ M, SANCF1EZ DJ, LLOBET JM, KEEN CL: Tiron administration minimizes the toxicity of vanadate but not its insulinomimetic properties in diabetic rats. Life Sci. (1992) 50:1311–1317.
   PubMed Web of Science ®Google Scholar
• MONGOLD JJ, CROS GH, VIAN L, TEP A, RAMANADIIAM S, SIOLJ G, DIAZ J, McNEILL JH, SERRANO JJ: Toxicological aspects of vanadyl sulfate on diabetic rats: effects on vanadium levels and pancreatic 13-celL Morphology Phar-macology and Toxicology (1990) 67:192–198.
   Google Scholar